

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 February 2009 (12.02.2009)

PCT

(10) International Publication Number
WO 2009/019163 A1

(51) International Patent Classification:
C07D 401/08 (2006.01) **C07D 401/06** (2006.01)

RIEMER, Claus [DE/DE]; Dreikoenigstrasse 31, 79102
Freiburg (DE). **WU, Xihan** [CN/CN]; Apartment 8-902,
567 Jinan East Road, Shanghai, 201204 (CN).

(21) International Application Number:
PCT/EP2008/059908

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124,
CH-4070 Basel (CH).

(22) International Filing Date: 29 July 2008 (29.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07113942.2 7 August 2007 (07.08.2007) EP

(71) Applicant (for all designated States except US): **F. HOFF-
MANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse
124, CH-4070 Basel (CH).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **JABLONSKI,
Philippe** [FR/FR]; 2, rue de Luemschwiller, F-68440
Steinbrunn-le-Haut (FR). **KAWASAKI, Kenichi** [JP/JP];
506 Lions Plaza Shounan Fujisawa, 968-1 Fujisawa, Fuji-
sawa-shi, Kanagawa-ken 251-0052 (JP). **KNUST, Henner**
[DE/DE]; Im Ortsetter 26a, 79618 Rheinfelden (DE).
LIMBERG, Anja [DE/CH]; Wettsteinallee 105, CH-4058
Basel (CH). **NETTEKOVEN, Matthias** [DE/DE]; Ruet-
teweg 3, 79639 Grenzach-Wyhlen (DE). **RATNI, Hasane**
[FR/FR]; Louis Pasteur 4, F-68440 Habsheim (FR).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,
NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(54) Title: PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS



(I)

(57) Abstract: The invention relates to a compound of general formula (I) wherein Ar¹ is aryl or a five or six membered heteroaryl; Ar² is aryl or a five or six membered heteroaryl; R¹ is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O)₂-lower alkyl, -S(O)₂-di-lower alkyl amino, -(CH₂)_qR, cyano, amino, mono or di-lower alkyl amino, NHC(O)-lower alkyl, cycloalkyl or is or a five membered heteroaryl, optionally substituted by lower alkyl; wherein R is cyano, di-lower alkyl amino or pyrrolidin-1-yl; R² is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; R³ is hydrogen or lower alkyl or

CH₂OH; R⁴ is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; n is 1, 2 or 3; in case n is 2 or 3, R¹ may be the same or different; o is 1, 2 or 3; in case o is 2 or 3, R² may be the same or different; p is 1, 2 or 3; in case p is 2 or 3, R⁴ may be the same or different; q is 1 or 2; or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).